Using fecal microbiota transplantation to eliminate drug-resistant bacteria from the gut

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of fecal microbiota transplantation (FMT) to eradicate intestinal colonization by carbapenem-resistant Enterobacteriaceae (CRE). The study aims to evaluate the efficacy of FMT from donors with limited antibiotic resistance genes in a randomized controlled setting. Participants will be monitored for clinical efficacy and the clearance of antibiotic resistance genes, with the goal of restoring healthy gut microbiota to combat multi-drug-resistant bacteria. The trial is designed to provide established evidence for FMT as a treatment option for infections caused by these resistant bacteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \>18 years;
* CRE diagnosed with rectal swab \<15 days before evaluation;
* Ability to undergo study procedures and to give informed consent.

Exclusion Criteria:

* Active chronic gastrointestinal disorders;
* Previous colorectal surgery;
* Major comorbidities;
* Pregnancy/breastfeeding;
* Psychiatric disorders.

Where it's running

• Giovanni Cammarota
  Roma, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using fecal microbiota transplantation to treat antibiotic-resistant infections

  This study is testing whether a treatment using healthy gut bacteria from donors can help people get rid of hard-to-treat infections caused by antibiotic-resistant germs.

  Recruiting Phase 1/2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT04759001

• Aztreonam-Avibactam in Immunocompromised Patients with Multidrug-Resistant Infections

  This study tests how well and how safely aztreonam-avibactam works in adults with weakened immune systems who have highly resistant Enterobacterales infections.

  Recruiting Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · Buenos Aires, City of Buenos Aires · NCT07890480

• Using fecal transplantation to eliminate drug-resistant bacteria

  This study is testing whether using fecal transplants can help adults get rid of harmful drug-resistant bacteria in their gut.

  Recruiting Phase 3 Assistance Publique - Hôpitaux de Paris · Clichy and 10 other locations · NCT05035342

• Isolation of therapeutic antibodies against Pseudomonas aeruginosa

  This study is trying to find new antibodies from patients to help treat infections caused by the tough-to-treat bacteria Pseudomonas aeruginosa.

  Recruiting University Hospital, Grenoble · Grenoble · NCT04335383

• Comparing two antibiotics for treating bloodstream infections from resistant bacteria

  This study is testing if a new antibiotic called piperacillin-tazobactam works as well as meropenem for treating bloodstream infections caused by resistant bacteria in adults.

  Recruiting at 14 sites Phase 4 Rambam Health Care Campus · Calgary, Alberta and 13 other locations · NCT03671967

• Rectal swab detection of ESBL, carbapenemases, and high-level cephalosporinase to predict C3G-resistant Enterobacteriaceae infections in ICU patients

  This study tests whether a rectal swab that finds ESBL, carbapenemases, or high-level cephalosporinase can predict which adult ICU patients at Strasbourg are likely to get C3G-resistant Enterobacteriaceae infections.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07345923

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.